Financhill
Buy
51

NKTR Quote, Financials, Valuation and Earnings

Last price:
$24.18
Seasonality move :
2.04%
Day range:
$23.06 - $24.73
52-week range:
$6.48 - $37.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.81x
P/B ratio:
21.49x
Volume:
1.2M
Avg. volume:
3.4M
1-year change:
13.33%
Market cap:
$295.3M
Revenue:
$98.4M
EPS (TTM):
-$9.60

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NKTR
Nektar Therapeutics
$9.4M -$3.12 -54.72% -25.7% $94.83
BMY
Bristol-Myers Squibb
$11.4B $1.27 -2.15% 185.68% $57.01
CTOR
Citius Oncology
-- -- -- -- $3.00
INMB
INmune Bio
-- -$0.39 -100% -12.5% $7.65
LLY
Eli Lilly and
$14.6B $5.54 34.58% 472% $952.27
NOTV
Inotiv
$127.1M -$0.15 20.1% -85% $5.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NKTR
Nektar Therapeutics
$23.80 $94.83 $295.3M -- $0.00 0% 3.81x
BMY
Bristol-Myers Squibb
$46.43 $57.01 $94.5B 17.39x $0.62 5.3% 1.98x
CTOR
Citius Oncology
$1.54 $3.00 $110.2M -- $0.00 0% --
INMB
INmune Bio
$2.07 $7.65 $48M -- $0.00 0% 1,061.01x
LLY
Eli Lilly and
$771.75 $952.27 $692.8B 62.80x $1.50 0.73% 14.22x
NOTV
Inotiv
$1.85 $5.50 $63.6M -- $0.00 0% 0.11x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NKTR
Nektar Therapeutics
-- 4.404 -- 3.11x
BMY
Bristol-Myers Squibb
74.09% 0.148 41.04% 1.10x
CTOR
Citius Oncology
-- 9.770 -- --
INMB
INmune Bio
-- -0.993 -- 2.62x
LLY
Eli Lilly and
70.96% -0.134 5.19% 0.57x
NOTV
Inotiv
71.7% 5.380 526.33% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NKTR
Nektar Therapeutics
$10.5M -$44.4M -201.73% -201.73% -395.75% -$49.1M
BMY
Bristol-Myers Squibb
$8.2B $3.5B 7.93% 32.01% 30.94% $1.7B
CTOR
Citius Oncology
-- -$7.5M -- -- -- --
INMB
INmune Bio
-- -$9.9M -112.4% -122.48% -19810% -$6.8M
LLY
Eli Lilly and
$10.5B $5.4B 24.21% 78.25% 29.07% -$1.6B
NOTV
Inotiv
$29M -$9.5M -15.4% -49.29% -2.04% -$18.3M

Nektar Therapeutics vs. Competitors

  • Which has Higher Returns NKTR or BMY?

    Bristol-Myers Squibb has a net margin of -486.44% compared to Nektar Therapeutics's net margin of 21.93%. Nektar Therapeutics's return on equity of -201.73% beat Bristol-Myers Squibb's return on equity of 32.01%.

    Company Gross Margin Earnings Per Share Invested Capital
    NKTR
    Nektar Therapeutics
    72.66% -$3.60 $13.7M
    BMY
    Bristol-Myers Squibb
    72.92% $1.20 $67.2B
  • What do Analysts Say About NKTR or BMY?

    Nektar Therapeutics has a consensus price target of $94.83, signalling upside risk potential of 298.46%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.01 which suggests that it could grow by 22.78%. Given that Nektar Therapeutics has higher upside potential than Bristol-Myers Squibb, analysts believe Nektar Therapeutics is more attractive than Bristol-Myers Squibb.

    Company Buy Ratings Hold Ratings Sell Ratings
    NKTR
    Nektar Therapeutics
    4 1 0
    BMY
    Bristol-Myers Squibb
    3 18 1
  • Is NKTR or BMY More Risky?

    Nektar Therapeutics has a beta of 0.941, which suggesting that the stock is 5.928% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.363, suggesting its less volatile than the S&P 500 by 63.75%.

  • Which is a Better Dividend Stock NKTR or BMY?

    Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 5.3% to investors and pays a quarterly dividend of $0.62 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

  • Which has Better Financial Ratios NKTR or BMY?

    Nektar Therapeutics quarterly revenues are $10.5M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Nektar Therapeutics's net income of -$50.9M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is 17.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 3.81x versus 1.98x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NKTR
    Nektar Therapeutics
    3.81x -- $10.5M -$50.9M
    BMY
    Bristol-Myers Squibb
    1.98x 17.39x $11.2B $2.5B
  • Which has Higher Returns NKTR or CTOR?

    Citius Oncology has a net margin of -486.44% compared to Nektar Therapeutics's net margin of --. Nektar Therapeutics's return on equity of -201.73% beat Citius Oncology's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NKTR
    Nektar Therapeutics
    72.66% -$3.60 $13.7M
    CTOR
    Citius Oncology
    -- -$0.11 --
  • What do Analysts Say About NKTR or CTOR?

    Nektar Therapeutics has a consensus price target of $94.83, signalling upside risk potential of 298.46%. On the other hand Citius Oncology has an analysts' consensus of $3.00 which suggests that it could grow by 94.81%. Given that Nektar Therapeutics has higher upside potential than Citius Oncology, analysts believe Nektar Therapeutics is more attractive than Citius Oncology.

    Company Buy Ratings Hold Ratings Sell Ratings
    NKTR
    Nektar Therapeutics
    4 1 0
    CTOR
    Citius Oncology
    0 1 0
  • Is NKTR or CTOR More Risky?

    Nektar Therapeutics has a beta of 0.941, which suggesting that the stock is 5.928% less volatile than S&P 500. In comparison Citius Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock NKTR or CTOR?

    Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Citius Oncology pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NKTR or CTOR?

    Nektar Therapeutics quarterly revenues are $10.5M, which are larger than Citius Oncology quarterly revenues of --. Nektar Therapeutics's net income of -$50.9M is lower than Citius Oncology's net income of -$7.7M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Citius Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 3.81x versus -- for Citius Oncology. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NKTR
    Nektar Therapeutics
    3.81x -- $10.5M -$50.9M
    CTOR
    Citius Oncology
    -- -- -- -$7.7M
  • Which has Higher Returns NKTR or INMB?

    INmune Bio has a net margin of -486.44% compared to Nektar Therapeutics's net margin of -19478%. Nektar Therapeutics's return on equity of -201.73% beat INmune Bio's return on equity of -122.48%.

    Company Gross Margin Earnings Per Share Invested Capital
    NKTR
    Nektar Therapeutics
    72.66% -$3.60 $13.7M
    INMB
    INmune Bio
    -- -$0.43 $29.7M
  • What do Analysts Say About NKTR or INMB?

    Nektar Therapeutics has a consensus price target of $94.83, signalling upside risk potential of 298.46%. On the other hand INmune Bio has an analysts' consensus of $7.65 which suggests that it could grow by 137.68%. Given that Nektar Therapeutics has higher upside potential than INmune Bio, analysts believe Nektar Therapeutics is more attractive than INmune Bio.

    Company Buy Ratings Hold Ratings Sell Ratings
    NKTR
    Nektar Therapeutics
    4 1 0
    INMB
    INmune Bio
    2 2 0
  • Is NKTR or INMB More Risky?

    Nektar Therapeutics has a beta of 0.941, which suggesting that the stock is 5.928% less volatile than S&P 500. In comparison INmune Bio has a beta of 1.336, suggesting its more volatile than the S&P 500 by 33.612%.

  • Which is a Better Dividend Stock NKTR or INMB?

    Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INmune Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. INmune Bio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NKTR or INMB?

    Nektar Therapeutics quarterly revenues are $10.5M, which are larger than INmune Bio quarterly revenues of $50K. Nektar Therapeutics's net income of -$50.9M is lower than INmune Bio's net income of -$9.7M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while INmune Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 3.81x versus 1,061.01x for INmune Bio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NKTR
    Nektar Therapeutics
    3.81x -- $10.5M -$50.9M
    INMB
    INmune Bio
    1,061.01x -- $50K -$9.7M
  • Which has Higher Returns NKTR or LLY?

    Eli Lilly and has a net margin of -486.44% compared to Nektar Therapeutics's net margin of 21.68%. Nektar Therapeutics's return on equity of -201.73% beat Eli Lilly and's return on equity of 78.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    NKTR
    Nektar Therapeutics
    72.66% -$3.60 $13.7M
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
  • What do Analysts Say About NKTR or LLY?

    Nektar Therapeutics has a consensus price target of $94.83, signalling upside risk potential of 298.46%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 23.39%. Given that Nektar Therapeutics has higher upside potential than Eli Lilly and, analysts believe Nektar Therapeutics is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    NKTR
    Nektar Therapeutics
    4 1 0
    LLY
    Eli Lilly and
    18 4 1
  • Is NKTR or LLY More Risky?

    Nektar Therapeutics has a beta of 0.941, which suggesting that the stock is 5.928% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

  • Which is a Better Dividend Stock NKTR or LLY?

    Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.73% to investors and pays a quarterly dividend of $1.50 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NKTR or LLY?

    Nektar Therapeutics quarterly revenues are $10.5M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Nektar Therapeutics's net income of -$50.9M is lower than Eli Lilly and's net income of $2.8B. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 62.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 3.81x versus 14.22x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NKTR
    Nektar Therapeutics
    3.81x -- $10.5M -$50.9M
    LLY
    Eli Lilly and
    14.22x 62.80x $12.7B $2.8B
  • Which has Higher Returns NKTR or NOTV?

    Inotiv has a net margin of -486.44% compared to Nektar Therapeutics's net margin of -11.96%. Nektar Therapeutics's return on equity of -201.73% beat Inotiv's return on equity of -49.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    NKTR
    Nektar Therapeutics
    72.66% -$3.60 $13.7M
    NOTV
    Inotiv
    23.32% -$0.44 $557.2M
  • What do Analysts Say About NKTR or NOTV?

    Nektar Therapeutics has a consensus price target of $94.83, signalling upside risk potential of 298.46%. On the other hand Inotiv has an analysts' consensus of $5.50 which suggests that it could grow by 197.3%. Given that Nektar Therapeutics has higher upside potential than Inotiv, analysts believe Nektar Therapeutics is more attractive than Inotiv.

    Company Buy Ratings Hold Ratings Sell Ratings
    NKTR
    Nektar Therapeutics
    4 1 0
    NOTV
    Inotiv
    2 1 0
  • Is NKTR or NOTV More Risky?

    Nektar Therapeutics has a beta of 0.941, which suggesting that the stock is 5.928% less volatile than S&P 500. In comparison Inotiv has a beta of 3.939, suggesting its more volatile than the S&P 500 by 293.928%.

  • Which is a Better Dividend Stock NKTR or NOTV?

    Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inotiv offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Inotiv pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NKTR or NOTV?

    Nektar Therapeutics quarterly revenues are $10.5M, which are smaller than Inotiv quarterly revenues of $124.3M. Nektar Therapeutics's net income of -$50.9M is lower than Inotiv's net income of -$14.9M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Inotiv's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 3.81x versus 0.11x for Inotiv. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NKTR
    Nektar Therapeutics
    3.81x -- $10.5M -$50.9M
    NOTV
    Inotiv
    0.11x -- $124.3M -$14.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
71
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
61
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
78
SBET alert for Jul 16

SharpLink Gaming [SBET] is up 28.58% over the past day.

Buy
75
MP alert for Jul 16

MP Materials [MP] is up 0.48% over the past day.

Sell
38
NAIL alert for Jul 16

Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 2.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock